Latest News

ESC Congress 2025 Releases its Late-Breaking Scientific Programme
Written by: ESC Congress 2025 Scientific Programme
ESC Congress 2025 Releases its Late-Breaking Scientific Programme
Hot Line Sessions Revealed for ESC Congress 2025
Written by: ESC Congress 2025 Scientific Programme
Hot Line Sessions Revealed for ESC Congress 2025
IMPLEMENT-HF Initiative Raises Quadruple Therapy Use from 4.7% to 44.6% in Heart Failure Care
Written by: Radcliffe Cardiology
IMPLEMENT-HF Initiative Raises Quadruple Therapy Use from 4.7% to 44.6% in Heart Failure Care
Intravenous Ferric Carboxymaltose in FAIR-HF2 Trial Shows No Significant Reduction in Heart Failure Events but Improves Quality of Life
Written by: Radcliffe Cardiology
Intravenous Ferric Carboxymaltose in FAIR-HF2 Trial Shows No Significant Reduction in Heart Failure…
Study Finds Multimorbidity Dramatically Increases Mortality Risk in Heart Failure Patients with Mildly Reduced and Preserved Ejection Fraction
Written by: Radcliffe CKM
Study Finds Multimorbidity Dramatically Increases Mortality Risk in Heart Failure Patients with Mildly…
THT 2025 Conference Announces its Late-Breaking Scientific Sessions
Written by: THT
THT 2025 Conference Announces its Late-Breaking Scientific Sessions
Late-Breaking Trail and Featured Clinical Research Presentations Revealed for ACC Scientific Sessions 2025
Written by: ACC 2025
Late-Breaking Trial and Featured Clinical Research Presentations Revealed for ACC Scientific Sessions…
ESC Congress 2024 Reveals its Late-Breaking Scientific Sessions
Written by: ESC Congress
ESC Congress 2024 Reveals its Late-Breaking Scientific Sessions
ESC Congress 2024 Unveils its Hot Line Trials
Written by: ESC Congress
ESC Congress 2024 Unveils its Hot Line Trials
Timing of Cardio-Kidney Protection with SGLT2 Inhibitors
Written by: Radcliffe Cardiology
Timing of Cardio-Kidney Protection with SGLT2 Inhibitors

External news

Written by: Academic - advance access - HF
Intravenous IRON supplementation in Heart Failure with Preserved Ejection Fraction and iron deficiency (IRON-HFpEF): a comprehensive phase II multicentre placebo-controlled randomised clinical trial
Written by: Academic - open access - HF
Intravenous IRON supplementation in Heart Failure with Preserved Ejection Fraction and iron deficiency (IRON-HFpEF): a comprehensive phase II multicentre placebo-controlled randomised clinical trial
Written by: Academic - advance access - HF
Reply to “Letter regarding the article ‘Modification of the association between age and mortality in heart failure by frailty status”
Written by: Academic - advance access - HF
Letter regarding the article 'Modification of the association between age and mortality in heart failure by frailty status’
Written by: Academic - advance access - HF
Natriuretic Peptide Testing in Primary Care: The Evidence is Settled, Implementation is Not
Written by: Academic - advance access - HF
Iron deficiency and risk of heart failure and cardiovascular events in CKD: Insights from the ASCEND-ND trial
Written by: Academic - open access - HF
Improved Outcome up to Ten Years after Intravenous Immunoglobulin Therapy in Patients with Dilated Cardiomyopathy
Written by: Academic - advance access - HF
Improved Outcome up to Ten Years after Intravenous Immunoglobulin Therapy in Patients with Dilated Cardiomyopathy
Written by: Academic - advance access - HF
Prediction or speculation: heart failure models for diabetes
Written by: Academic - advance access - HF
Navigating unexplained dyspnoea and the role of HFpEF diagnostic scores